Member Info for HereforHemo

I’ve also been in communication with him and I can confirm that. I’m very happy to hold and accumulate.

I’m a relatively new investor here but with all management having substantial skin in the game, with options exercising up to 50p I’m happy to wait and see how this plays out.

There’s some serious financial players involved in this company and the recent pivot into digital aligning with both the US and UK (especially if Reform get in) I think they’ll definitely get first mover advantage before regulations get passed.

This is vastly undervalued in my opinion.

I think what we should be looking out for now is an announcement that enables CDX to be fast tracked into the clinic. That would move Hemogenyx from a product company to a platform company and put hundreds of millions on the purchase price, if indeed Vlad is looking to sell rather than go the strategic partner route.

Exciting times.

Coming.

To determine a fair buyout price we would use the rNPV (Risk-Adjusted Net Present Value), as this is the gold standard for biotech valuation because it accounts for the fact that a drug might fail its next trial.

Given the current progress—Cohort 1 success, DSMB clearance for Cohort 2, and the "Estonian revenue Shortcut"—the risk profile has dropped significantly.

1. The rNPV Calculation Parameters (current)

There are three "pillars" of the company. Everyone uses a 15% discount rate (standard for high-growth biotech) and adjust for the Probability of Technical and Regulatory Success (PTRS).

There’s the Asset, the Target Market (AML/HSC), the Peak Annual Revenue, the PTRS (Success Prob.)and Estimated Asset Value:

HG-CT-1 (CAR-T) $2.5B (US/EU) $650M 25% (Phase I/II) $162.5M

CDX Antibody $4.0B (Conditioning) $900M 15% (Pre-clinical) $135.0M

CBR Platform $10B+ (Solid/Viral) $1.5B (Licensing) 5% (Early Stage) $75.0M

Total Platform rNPV $372.5M (~£295M)

As of February 2026, Hemogenyx has approximately 6.04 million shares in issue so thr Conservative Buyout (Asset Value only): £295M / 6.04M shares = £48.84 per share. However, Big Pharma often pays a 30% "Platform Premium" to prevent competitors from owning the tech. This pushes the valuation to ~$480M (£380M) which would equate to a share price of £62.91.

But here’s the exciting part. The above only values CBR at $75m. Any progress on this candidate would likely see the price triple. Any progress in getting CDX fast tracked into the clinic would see a substantial rise in the value of the candidate and of most importantly publishing both good safety and efficacy results of the dose escalation of Patient 4 would eliminate all doubt for a pharmaceutical major, it would turn Hemogenyx from a maybe to a must have to dominate the AML landscape.

It would immediately turn Hemogenyx into an £800m to £1.2bn company and we’d be looking at an SP closer to £155.

Just my thoughts.

I try never to advise anyone to buy anything and I’m deeply suspicious of anyone who does.

What I will say is that I’m holding onto all my shares in Hemogenyx and I think everyone will realise why that is in the very near future.

Matt if the technology transfer is announced next week as i expect, patient 4 passing safety in dose escalation might only be around 5 weeks away. With the first child being injected straight after patient 4, their safety results could follow a matter of days from patient 4.

Personally I don’t think we’re too far away from getting proper value assigned, by that I mean multiples of today’s share price.

I’m pretty certain the technology transfer announcement will be made this month. Furthermore from looking at their financial statements, and including the warrants exercised at the end of last year, I believe as they haven’t been treating patients they should have around £2m still in the bank. With a vastly reduced burn rate that could and should last them until the end of Q2. However I believe they’ll be bought long before then.

When you look at Hemogenyx now, with a vastly reduced burn rate, warrants being cleared and the move to a commercially scalable manufacturing process coupled with the internal governance and executive incentives, such as accelerated vesting of options and Vlad being awarded a years salary in advance, everything aligns perfectly with a "Change of Control" event coming.

To determine a fair buyout price we would have use the rNPV (Risk-Adjusted Net Present Value), as this is the gold standard for biotech valuation because it accounts for the fact that a drug might fail its next trial. Given the current progress—Cohort 1 success, DSMB clearance for Cohort 2, and the "Estonian revenue Shortcut"—the risk profile has dropped significantly.

1. The rNPV Calculation Parameters (current)

There are three "pillars" of the company. Everyone uses a 15% discount rate (standard for high-growth biotech) and adjust for the Probability of Technical and Regulatory Success (PTRS).

There’s the Asset, the Target Market (AML/HSC), the Peak Annual Revenue, the PTRS (Success Prob.)and Estimated Asset Value:

HG-CT-1 (CAR-T) $2.5B (US/EU) $650M 25% (Phase I/II) $162.5M

CDX Antibody $4.0B (Conditioning) $900M 15% (Pre-clinical) $135.0M

CBR Platform $10B+ (Solid/Viral) $1.5B (Licensing) 5% (Early Stage) $75.0M

Total Platform rNPV $372.5M (~£295M)

As of February 2026, Hemogenyx has approximately 6.04 million shares in issue so thr Conservative Buyout (Asset Value only): £295M / 6.04M shares = £48.84 per share. However, Big Pharma often pays a 30% "Platform Premium" to prevent competitors from owning the tech. This pushes the valuation to ~$480M (£380M) which would equate to a share price of £62.91.

But here’s the exciting part. The above only values CBR at $35m. Any progress on this candidate would likely see the price triple. Any progress in getting CDX fast tracked into the clinic would see a substantial rise in the value of the candidate and of most importantly publishing both good safety and efficacy results of the dose escalation of Patient 4 would eliminate all doubt for a pharmaceutical major, it would turn Hemogenyx from a maybe to a must have to dominate the AML landscape.

It would immediately turn Hemogenyx into an £800m to £1.2bn company and we’d be looking at an SP closer to £155.

That’s how I see it anyway.

Mornington rest assured there’s plenty of good news on the way, not least patient one (god willing) achieving the tremendous milestone of being alive for one year following treatment in a matter of only 12 trading days.

That news alone should eliminate the ‘London discount’ and bring parity to peer level stocks in the US. Benefit to investors, a three fold increase in the share price.

Pumpky nearly right, there is £1.1m already allocated from their existing cash to Made Scientific in order to progress treatment quickly upon enrolment.

All approved. Initially interesting for CAR-T but ultimately for both CBR and CDX as well.

https://www.fiercepharma.com/pharma/house-endorses-bill-would-revive-fdas-rare-pediatric-review-voucher-program?itm_source=parsely-api

I hope all investors realise what all of our largest shareholders do, and why it appears institutional investors have joined retail in pushing the share price up.

First there’s the ‘London discount’ where peer level companies listed on the Nasdaq are traditionally valued at up to five times the value of a company listed on the London exchange. This is of little concern to our largest holders as all that matters to them is the data, for example once patient one reaches their year milestone later this month the product will show definitive durability and move towards being curative. This alone will eliminate the discount and Hemogenyx will be viewed globally and valued equally to its peers.

Then there is the imminent dose escalation treatment. Pass safety with no adverse effects would again likely see a major spike in the share price as it would likely see even better efficacy and cement its designation of being a breakthrough curative therapy.

Then there is pediatrics, the holy grail for this is a totally untapped market where successful treatment of just one patient is virtually guaranteed, in my opinion to gain Orphan Drug Designation from the FDA, allowing tax credits, fast tracking, grants as well as a seven year exclusively period. Likely to double the share price.

Finally, having a tier one company like Made Scientific to have a globally scalable process would be extremely well received by the FDA, allowing them to fast track the product to at least Phase 3 as well as providing a major catalyst for majors to move.

I think I speak for the vast majority of long term investors when I say we view Hemogenyx as a billion dollar company in the making. All of the building blocks are in place, just with CAR-T. Add in CDX and CBR then we’re into Vlads latest comment.

“The sky is the limit”.

It’s important to realise how important the MD Anderson Cancer Centre is, being the leading cancer centre in the world as they have extensive and formal discussions with all the major pharmaceutical companies. These interactions go far beyond simple clinical trial participation and are often structured as Strategic Alliances.

MD Anderson is actually a pioneer in how academic medical centers collaborate with the "Big Pharma" industry. Rather than just acting as a site to test a drug, they often engage in deep, multi-year partnerships to co-develop therapies.

MD Anderson's Strategic Industry Ventures office manages these high-level relationships. Their discussions typically cover:

Strategic Alliances: Long-term agreements (often 5+ years) where MD Anderson and a pharma company agree to share data, research platforms, and clinical expertise to move a drug from the lab to the clinic and beyond.

Joint Ventures: In some cases, they form entirely new companies with industry partners to commercialise specific technologies, such as their work with National Resilience to create CTMC (Cell Therapy Manufacturing Centre).

Translational Research: Discussions often focus on "reverse translation," where MD Anderson uses its vast patient data to help pharmaceutical companies understand why a drug worked in some patients but not others.

MD Anderson has high-profile alliances with all of the world's top twenty pharmaceutical and biotech firms, so regardless of Vlad’s direct discussions with multiple pharmas and other organisations, I feel sure that all relevant companies will be very aware of Hemogenyx and their clinical progress.

So in short, a partner could literally come from nowhere at any time and as others have eluded to, the more patients that are treated and the longer they remain alive it’s a simple fact that the more valuable the product becomes. Therein lies the dilemma for pharma. Do they wait for more data and pay more, which is usually what the larger pharmaceutical companies do, or do they take on more risk and move early, which is typically what thre mid range pharmaceutical companies do. And if one bids..what will the others do?

Interesting times ahead.

Lostapound the important thing is Vlad is negotiating from a position of strength. I would guess that Vlad would say to any pharma he’s negotiating with until you put your money on the table I’ll talk to who I want.

The good news is I think we’ll find out sooner rather than later.

Mike I’d say patient one reaching one year from treatment on the 24th would be a major milestone. Firstly because it would actually be around 15 months from initial diagnosis which would undoubtedly put it in breakthrough therapy territory and suitable for FDA fast tracking and grants. Secondly because Hemogenyx should release precise safety and efficacy reports as outlined by MD Anderson.

As regards company valuation it’s hard to say. What I think would be widely agreed upon is hitting this milestone makes HG-CT-1 a $500m to a $1bn product even at this early stage. That would make the SP, in theory, anything up to £165 a share.

Its real, even a leader in CAR-T will need to go on the acquisition trail

https://www.fiercepharma.com/pharma/novartis-ceo-projects-2026-growth-despite-largest-patent-expiry-company-history

Lostapound I thought you asked a valid question on this occasion. Personally I’ve never ramped up any conference but it’s fair to say there are far more investors at them than the traditional VC’s so I’d say all visibility is good.

As for funding, I’m sure if a VC offered $50m Vlad would accept it, but only on his terms. But, funding will definitely be coming from big pharma, I’m sure of that.

Matt if Hemogenyx releases efficacy data upon patient one being alive for one year after treatment along with the other two patients being alive and well after many months, and they confirm the technology transfer is complete with the first dose escalation patient and first child chosen, and a multi million investment in CAR-T and/or CDX I’d be hugely disappointed with a £15 share price. It would be double that imo.

Moorscloud, I envisage Hemogenyx selling the company without CBR. I think it’ll be spun off into another company for Vlad to run.

Moorscloud my feeling is any pharmaceutical company interested in HG-CT-1 would want CDX as well due to the scientific synergies that exist within the two products. If I’m correct it would make more sense to purchase the company outright.

However, they are unlikely to value CDX as Vlad does, so if he engineered a way to outline a roadmap to fast track CDX into the clinic he would then assign a correct value to the company as a whole.

My guess is that’s precisely what he intends to do.

Following the statement from Hemogenyx that they were reasonably confident of securing funding from a major pharmaceutical company regarding HG-CT-1, based upon the promising data from the first cohort of patients (beyond promising imo as all three patients remain alive and the first fast approaching one year since treatment. I think that’s transformational and remarkable), investors shouldn’t lose sight of just how much this derisks another candidate, their CDX bi-specific antibody, which could actually be far more valuable than HG-CT-1.

So whilst everyone is focusing on CAR-T and the ongoing trials I wouldn’t be at all surprised if the recent rise in the SP wasn’t connected to CAR-T at all.

I’m expecting a pretty major announcement on CDX.

Just my view.